01602D64-57C5-4D95-A6F9-5FB124D398B1
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 95.86070959264126
- age_years
- 36
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.550
- TNFA_SIGNALING_VIA_NFKB+0.547
- NOTCH_SIGNALING+0.452
- IL6_JAK_STAT3_SIGNALING+0.449
- APOPTOSIS+0.435
- INTERFERON_ALPHA_RESPONSE+0.392
- COMPLEMENT+0.382
- WNT_BETA_CATENIN_SIGNALING+0.378
- INFLAMMATORY_RESPONSE+0.376
- IL2_STAT5_SIGNALING+0.373
Top 10 suppressed
- KRAS_SIGNALING_DN-0.285
- SPERMATOGENESIS-0.258
- OXIDATIVE_PHOSPHORYLATION-0.236
- PANCREAS_BETA_CELLS-0.084
- PEROXISOME-0.043
- G2M_CHECKPOINT-0.012
- MYOGENESIS+0.001
- E2F_TARGETS+0.014
- ESTROGEN_RESPONSE_LATE+0.036
- APICAL_JUNCTION+0.054
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 2D0A1BA3-EC1D-4B4F-A383-9353C0F4BE85 | — | — | 0.917 |
| 2 | 7E4D42B3-FD9B-4184-A4A0-E52E45259428 | — | — | 0.917 |
| 3 | SRR934807 | — | — | 0.916 |
| 4 | SRR934750 | — | — | 0.910 |
| 5 | 12B24051-5657-45E8-9C64-5B6A06693471 | — | — | 0.908 |
| 6 | A3874F0D-53A9-43C8-87EE-65C12C0F8135 | — | — | 0.904 |
| 7 | SRR934952 | — | — | 0.904 |
| 8 | SRR934987 | — | — | 0.902 |
| 9 | SRR934845 | — | — | 0.902 |
| 10 | 18D7DFBC-A1C6-4DA8-9AF1-3A6F3E2A03BE | — | — | 0.901 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 44 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.550 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.547 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.452 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.449 | Inavolisib | — uncovered |
| APOPTOSIS | 0.435 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.392 | Inavolisib | — uncovered |
| COMPLEMENT | 0.382 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.378 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.376 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.373 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.365 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.359 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.335 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.325 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.304 | Idelalisib | — uncovered |
| COAGULATION | 0.286 | Binimetinib | — uncovered |
| HYPOXIA | 0.286 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.261 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.252 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.235 | Idelalisib | — uncovered |